Thursday, 17th September 2020  
« La Rentrée »
After a hot summer and family time, we are now in a «wait and see» approach amid warnings of a second wave of COVID-19. What did we learn so far?
First, the clusters were not national but regional and the solution is no longer a complete Member State lockdown but instead the implementation of mobility limitation between regions.
The second lesson is that, if a second crisis occurs, the EU could be a solution by providing hospitalization capacity for saturated local healthcare systems.
This prospect was considered during our discussion with top-level managers of big hospital groups who embraced this possibility, observing that, at the height of the pandemic, some hospitals were empty while others were overwhelmed. The right repartition of bed occupation according to a European mapping (and not national) could be the key.
We must remain careful while no vaccine is yet available and personal protection is our only safety solution. But do not forget the power of EU27 as a real safety zone for all European citizens with the full implication of the private hospital sector that UEHP represents. And Thursday 17 September the Patient Safety Day is an important event reflecting our every day work, UEHP supports this international event led by WHO.
Dr Paul Garassus
President of UEHP
Ursula von der Leyen’ first annual speech on the state of the EU
On 16 September, the European Commission's President, Ursula von der Leyen, held her first annual speech on the state of the EU to the European Parliament.
Usually, health policy is lucky to be mentioned at all during a State of the Union address. (Commission President Jean Claude Juncker rarely discussed health policy — except for an unusual intervention on vaccines in 2017 that led to the star-studded vaccine summit in 2019.) That changed this time around, when Commission President Ursula von der Leyen delivered her first address this morning and layed out some lessons of the coronavirus pandemic for future EU health initiatives.
It’s time for the European Union to bolster its health competence, European Commission President Ursula von der Leyen said today. “It is crystal clear: We need to build a strong European health union,” von der Leyen said. “It is time to do that.”
One of her key proposals is creating a European version of the U.S. Biomedical Advanced Research and Development Authority (BARDA) to help the EU better respond during emergencies relating to cross-border threats.The EU also needs strategic stockpiling and should fix its supply chain issues, especially for pharmaceutical goods, she said.Furthermore, she noted, there’s a need to “reinforce” existing European health agencies such as the European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC). More broadly, it’s “clearer than ever that we must discuss the question of health competencies” at the Conference on the Future of Europe, she said, drawing applause from parliamentarians. The Commission president also mentioned the EU4Health program, which was cut from nearly €10 billion to nearly €2 billion during negotiations with the Council over the bloc’s long-term budget. Von der Leyen said it’s time to make the program “future proof,” and added she’s “grateful” that the European Parliament will “fight for more” money. Last, von der Leyen said, she will convene a global health summit in Italy next year, when Italy will head the G20 Presidency.
Specifically on the EU action to fight the pandemic, President Ursula von der Leyen patted Europe on the back today for not adopting a “Europe first” policy when it comes to its coronavirus response. Without naming names, von der Leyen noted that other countries chose to “retreat into isolation” while others opted to “actively destabilize the system.” By contrast, “Europe chose to reach out,” she said, as she delivered her first speech on the state of the EU to MEPs. As an example, she cited the EU’s decision to send planes with tons of medical equipment to countries in need, including Sudan, Venezuela and Somalia. Most notably, however, von der Leyen pointed to the Commission’s work in establishing the Coronavirus Global Response. After two online events, it has raised roughly €16 billion toward ensuring global access to affordable vaccines, therapeutics and tests. “At the beginning of the pandemic, there was no funding, no global framework for a COVID-19 vaccine,” she said. “There was just the rush to be the first one to get one.” She pointed to how the Commission pledged €400 million toward the COVAX facility, an effort by the World Health Organization and Gavi, the Vaccine Alliance, to get wealthier countries to help finance vaccines for low- and middle-income countries. Furthermore, Von der Leyen said, Europe should take the lead in reforming the WHO.
She made those comments amid ongoing criticism that the Commission’s vaccine strategy — which it unveiled in June to allow Brussels to advance purchase coronavirus vaccines — is de facto a “Europe First” policy. The Commission’s involvement with COVAX is also unclear, as it has yet to clarify whether it will procure vaccines through the facility or just give money.
Those are the key takeaway for healthcare from today's speech in front of the European parliament. If you wish to read more on the full speech: click here
UEHP speaks at the HFE webinar "Patient safety: sharing best practices across Europe"
Last 8 September, Health First Europe organised a webinar debate on patient safety and best practices in Europe, in view of the Patient safety Day on 17 September.
The purpose of the discussion was to bring together healthcare authorities, patients, healthcare providers and workers as well as EU policymakers to debate the current landscape surrounding patient safety in Europe and showcase the patient safety success stories from across Europe's regions and local governments.
Patient safety remains a challenge for European healthcare systems. According to the World Health Organisation (WHO), medication errors and healthcare-related adverse events occur in 8% to 12% of the hospitalizations in Europe. Nearly half of the harm is believed to be preventable. Lapses in safety not only result in significant patient suffering but represent a considerable financial burden as well. The Organisation for Economic Co-operation and Development (OECD) estimates that direct costs of unnecessary harm to patients can amount to as much as 5% of total health expenditure.
The Keynote contributors included representatives from:
  • ECDC - European Centre for Disease Prevention and Control
  • The European Parliament
  • UEHP - European Union of Private Hospitals
  • IAPO - International Alliance of Patients' Organizations
  • University of Ferrara (Italy) 
Our President, Dr Garassus, who spoke on behalf of UEHP, brought the perspective of the private hospitals sector to the discussion, highlighting that we are not only speaking about patient safety but also about healthcare workforce safety! After reviewing some of definitions of safety and quality of care by WHO, College of Europe, etc. our President presented two concrete exemples of clinical risk management in two private hospitals group in germany, Asklepios and Sana Kliniken. Finally , Dr Garassus presented our concept of “Smart Hospitals” and stressed the need for inclusive reforms and sustainable investments to enhance efficient solutions, reduce waiting lists, limit waste and ensure permanent information available for medical staff and managers.
UEHP/WelcomeEurope Webinar - 28th September, 14.00
EU funding programmes
The UEHP webinar on EU funding programmes, organised in close partnership with WelcomeEurope, an independent organisation providing consultancy services and trainings on European Affairs and EU funding, will be held on Monday, 28th September, 14.00h – 15.30h. 
The aim is to offer you a clear and common vision of upcoming opportunities related to:
  • European structural and investment funds managed at national/regional levels
  • Funds directly managed by the European Commission
  • EU Recovery plan - Next Generation EU
Not only the webinar will be the opportunity to learn more about EU funding programs, but also to ask questions to the experts for each of the above-mentioned themes. 
On the initiative of our President, we believe the webinar will be useful to you and especially to your own members willing to know more about EU funding and how to apply to European call for proposals. Please feel free to forward this invitation to your members and network.  
The webinar is free of charge, but the prior registration is mandatory. Please register at the following address: here
UEHP/EAASM Online event - 30th September, 14.00
“Patient safety and the implementation of the Falsified Medicines Directive in the hospital environment – one year on”
As you may recall, this event, that UEHP is organizing in cooperation with the European Alliance for Access to Safe Medicines (EAASM), was initially scheduled in March at the European Parliament. Unfortunately, we had to postpone it due to the COVID19 pandemic and since the situation is still difficult (especially in Brussels), we finally decided with the organizers to turn it to an online event. 
You are all encouraged to take part in the event and to share this invitation with your own members and colleagues who could be interested.
Please find here the draft agenda and link to register to the webinar. More information can be found at the EAASM website.
EU Health Summit – Online event 26 October
Lessons learnt from the COVID-19 pandemic
The EU Health Coalition is delighted to invite you to the EU Health Summit “Time for Action” which will go virtual on the 26th of October (13:30 – 17:30) with the participation of Commissioner Stella Kyriakides, Commissioner Mariya Gabriel and EU Presidency German Health Minister Jens Spahn
The COVID-19 pandemic has shown us the importance of cooperation between all sectors and actors to ensure our healthcare systems can function to their best ability in saving human lives.
In 2018, 33 organisations came together under the umbrella of the EU Health Coalition. They jointly developed 20 recommendations for a healthier Europe to promote a shared vision of health in Europe. A number of these have since been implemented including, most notably, giving a much larger role to health at EU level. Much still remains to be done!
This year, it is time for action. The continued and concrete implementation of the 2018 recommendations requires a broad support base as well as multi-stakeholder actions. For the second edition of the EU Health Summit, participants together with the EU Health Coalition partners, will develop implementing actions to continue to translate the 2018 recommendations into concrete policy change and improve Europeans’ health and health systems’ sustainability. Particular attention will be paid to the lessons learnt from the COVID-19 pandemic and how to translate these into a political vision capable of maximising collaboration and ensuring a healthy and equitable future for everyone in Europe.
You can find more information about the programme hereJoin us on the 26th of October at 13:30. Together, we are shaping the future of Health in Europe.
For more information please visit:
Register now
The EU Health Coalition was created following the first-ever EU Health Summit, in November 2018. The Coalition promotes a shared vision of health in Europe, based on jointly developed recommendations. The purpose is to ensure that health remains high on the political agenda and to champion the changes required to address the unprecedented challenges that an ageing population and an increasing prevalence of chronic diseases pose to healthcare systems and citizens.
The EU Health Coalition is composed of patient organisations, EU research-oriented medical societies, industry organisations, healthcare providers, regional and local health authorities and other relevant stakeholders, who all share a common vision. To find out more about the work of the EU Health Coalition, please visit our website here.
Update on the electronic cross-border health services
The European Commission has just published an update on the electronic cross-border health services available in the EU.
The electronic cross-border health service is an infrastructure ensuring the continuity of care for European citizens while they are travelling abroad in the EU. This gives EU countries the possibility to exchange health data in a secure, efficient and interoperable way. 
The following two electronic cross-border health services are currently progressively introduced in all EU countries:
  • ePrescription (and eDispensation) allows EU citizens to obtain their medication in a pharmacy located in another EU country, thanks to the online transfer of their electronic prescription from their country of residence where they are affiliated, to their country of travel.
  • Patient Summary provides information on important health related aspects such as allergies, current medication, previous illness, surgeries, etc. It is part of  a larger collection of health data called electronic Health Record. The digital Patient Summary is meant to provide doctors with essential information in their own language concerning the patient, when the patient comes from another EU country and there may be a linguistic barrier. On a longer term, not only the basic medical information of the Patient Summary, but the full Health Record should become available across the EU. The exchange of ePrescriptions and Patient Summaries is open to all the Member States.
Both ePrescriptions and Patient Summaries can be exchanged between EU countries thanks to the new eHealth Digital Service Infrastructure (eHDSI).
By 2021, both services will gradually be implemented in 22 EU countries: Austria, Belgium, Croatia, Cyprus, Czechia, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Portugal, Slovenia, Spain and Sweden.
UEHP in the media
World Vax War II
by Dr Paul Garassus & Dr Christian Hervé
Article released in French in Décision Santé Magazine – September 2020
The vaccine war has been declared. The announcement effect has politicians from all over the world and from all sides taking on the challenge and racing to develop a vaccine for the COVID-19 coronavirus.
As doctors, it is our conviction that in the face of this RNA virus against which we have no proven curative therapeutic means, the vaccine appears to be the needed solution to limit the pandemic. At this stage, we are fully aware of the commitment of the scientific research laboratories but also of the entire Big Phama to achieve this technological feat in the shortest possible time for the benefit of the world population.
But now, this competitive scenario poses a problem. The first international war for influence on vaccine strategies dates back to "Ottocento" with Pasteur. The significance of this new virus challenges us in technical and ethical terms while facing a potential conflict. Vladimir Putin has announced the success of the Russian research, the large industrial groups of the European or North American pharmaceutical sector have signed preferential allocation contracts with some national governments.
What are the expected benefits of such negotiations? Obviously, the short-term interest is the possibility for politicians to be able to shelter the people of their country from the dangers of viral infection. To limit lethal complications and medical problems, but also to it make possible to return once again to a "normal" life where students can go to school, workers return to their production force, and the elderly be kept safe from harm. The latter having already paid the heaviest price.
But medical nationalism, which de facto amounts to excluding our neighbours, near and far, from this therapeutic benefit, is very difficult to defend. Should we conceive that the competitive advantage of putting a production force back into working order with a lead over potential competitors, should be neglected in economic terms? No. And from a strategical standpoint to benefit from a dominant position? Neither. Ethically, on the other hand, this is not even conceivable.
Researchers are currently exploring different but often innovative avenues. We believe, without mastering the timeframe, in the effectiveness of these research commitments performed under pressure. This crisis will create, like any major event, a historic break in our globalized societies. Economic regulation will not weaken, its application methods will nevertheless evolve. Thus, a priority or a preference towards a single State would be untenable, both in terms of access time and authorization. Global public health will undoubtedly face a political and moral question. Who should benefit from the benefits of science, the financers or humanity as a whole? We know the logic involved in return on invested capital (ROIC) on the part of economic actors in health, as well as the strategic support for investment by engaged governments struggling for influence. Some healthcare companies involved in the creation of a new vaccine refer to the principle of an "ethical profit margin", which is a new concept yet to be defined. The possible strategic advantages obtained will be greatly argued but the principle of equal access must be privileged by following the recommendations of international organizations, in the first line of which is WHO.
The medical challenges will have to be anticipated because the potential problems are numerous: a possible iatrogenic reaction, even if in the best case it is less than 0.001% , it could be problematic if the vaccination covers 7.5 billion people. We also know that the authorization and safety procedures will have to constrain the usual delays. And what about legal protection for any innovation placed on the market, if similar ones are offered? Finally, the industrial process, beyond the discovery itself and we are talking about the production chain, remains a major organizational challenge to be resolved.
We have no doubt that medical ethics shall be part of the debate and we trust that it will triumph. Nationalism has no place in health, nor do the usual purely commercial reasonings. The political power struggle for the vaccine race, like the race for the moon in other times, is irrelevant. The virus is ubiquitous, its treatment must be quickly accessible to all. The great democracies must be able to demonstrate that they are the real vector of medical scientific progress, and that the collective benefit for the world population is the only legitimate target made possible by our combined financial means. In this regard, Europe must certainly get involved as a major player in social progress because the Second World Vaccine War or "World Vax War" must not take place.
Dr Paul GARASSUS, President of UEHP (European Union of Private Hospitals) and Vice-President of SFES (French Society of Health Economics)
Pr Christian HERVE Head of the Ethics and Scientific Integrity Department of Foch Hospital. University of Paris.
The pandemic has intensified the partnership between the public and private sectors
Interview with Dr. Eduardo Amaro, President of ANAHP, Brazilian Association of Private Hospitals
What is the market share of the private hospital sector in Brazil?
Of this total, R$ 285.90 billion were public resources (43.5% of the total) and R $ 371.67 billion were private resources (56.5% of the total). In the public sector, for 2019, expenditures of R$ 121.20 billion were forecast for the federal government, R$ 73.40 billion for state governments and R$ 91.30 billion for municipal governments. In the private sector, it is estimated that R$ 199.3 billion was paid by families and companies to fund medical and hospital assistance plans in 2019 and that private spending was R $ 172.4 billion.
The health market continues to generate a considerable volume of new formal jobs. In 2019, 93,000 new job opportunities were generated in the health sector, approximately half of which refer to hospital care activities (48,000 jobs created in 2019 against 37,000 in 2018). With the generation of 48,000 job opportunities, based on data from the 2018 of Annual Social Information List (Relatório Anual de Informações Sociais - Rais), the hospital sector must have reached the mark of 1,260 formal employees in 2019.
According to the latest data released by the National Register of Health Facilities (Cadastro Nacional de Estabelecimentos de Saúde - CNES) of June 2020, the total number of hospitals in the Brazilian territory is 6,252, of which 57% are private and 43% public.
Does the general population have access to private hospitals, in other words, do private hospitals are under contract with the government or do patients need to have a private insurance or pay out-of-pocket?
Brazil has the largest Public Health system in the world, which means that all citizens are entitled to free medical care. The private sector ends up being an important alternative for part of the population, who can access it privately or through health insurances plans, which today has about 47 million beneficiaries. Renowned private hospitals such as Hospital Albert Einstein and Hospital Beneficência Portuguesa de São Paulo provided beds, equipment and professionals to the Unified Health System (SUS).
Regarding Covid-19:
How has the private healthcare sector been affected by the pandemic in Brazil (in its organization and finances)?
Hospitals faced major challenges such as the drop in demand for services, the scarcity of Personal Protective Equipment, the increase in the cost of various hospital supplies, the need to review flows and to provide intense training for the teams. Now is the time to retake caring, which affects internal processes and flows that must ensure safety for patients, companions and health professionals.
Among Anahp hospitals, absenteeism grew 49.7% in the first half of this year compared to same period of the previous year.
According to a survey carried out by Anahp with its associates, there was also an increase in the cost of hospital supplies of around 300% and in the consumption of Personal Protective Equipment (PPE) by more than 200%.
The reduction in hospital revenue, added to the increase in variable expenses and the maintenance of fixed expenses, resulted in a 60% lower operating result in the first six months of 2020, compared to the same period last year.
How has the private healthcare sector in your country been included into the national emergency plan to face the pandemic?
The public and private health sectors played equally fundamental roles in combating covid-19 in Brazil. The union of the two sectors resulted in initiatives such as the creation of field hospitals, new research to combat the disease, sharing of best practices such as new protocols, beds provided by private hospitals for patients in the public sector, among others. Private hospitals were important agents in the evolution of care and safety protocols for infected patients, since the first cases in Brazil were treated in private hospitals. In the retaking activities process in the country, the supplementary health sector is inserted in crisis committees created by the government, with an important role in guiding decision-making by political leaders.
Did this health crisis bring changes (positive or negative) to the role of the private hospital sector within your national health system?
The pandemic has intensified the partnership between the public and private sectors, for the Brazilians health. Hospitals associated with Anahp played a key role in fighting the coronavirus and supported the public sector with the development of studies and research, sharing of best practices, provision of ICU beds and construction and management of field hospitals.
In addition, to face the challenges that arose in the midst of the crisis, such as an increase in the value of Personal Protective Equipment (PPE's), hospital supplies and medicines, regulation of beds and shortages of products and equipment, Anahp opened dialogue with other players in the sector. In this way, it was possible to resolve the issues with agility, as the situation requires, to continue guaranteeing the service.
What will remain after the crisis for the private healthcare sector (positive and negative issues)?
Not only for the private sector, but for health as a whole, the great legacy of facing this pandemic was the identification of the needs for more integrated planning between the public and private sectors; an information system that provides consistent and quality information for decision-making; to develop a national production of critical supplies and the importance of telemedicine.
The Italian situation after the first pandemic summer
By Niccolò de Arcayne, Head of Institutional and International Affairs at AIOP (Italian Association of Private Hospitals)
In Italy, after the end of the “Phase 1” of the Covid-19 emergency, that has been shaped by a general freezing – with single Regional Council decisions – of the regular (outpatient) activity provided by public and private hospitals in all the 20 Regions, the general situation is returning to normal.
During the summer, after the steady improvements related to the reduction of the number of new Covid-19 cases, in certain Italian regions we had been sadly witnessing a new growing of contagion, due to the progressive re-opening of the major social gathering places.
For this reason, on August 12, the Council of Ministers issued an Order that obliged all the Italian citizens and the incoming tourists arriving from holiday destinations (Croatia, Greece, Malta and Spain) to demonstrate the absence of Covid-19 infection. All citizens and visitors are now obliged to submit to the health authorities a molecular or antigen test, with a negative result, carried out in the previous 72 hours in the country of origin, or eventually proceed with rapid tests experimentally adopted in the main Italian airports or within 48 hours from the entrance to Italy.
The measures contained in the Order also include the ban on entry and transit from Colombia, recently added to the list of “countries at risk”.
Last Week, the Council of Ministers approved the extension of the health emergency to October 15, to ensure the mantainance and the operativeness of all the measures adopted from the beginning of the “Phase 1” of the emergency, and contain in the best way possible the diffusion of the virus.
In general, public and private hospitals are now efficiently managing the new Covid-19 cases, but it is definitely important to underline how this general situation have determined a negative economic impact on the business of private hospitals. For many reasons, including the fear of patients that are afraid of visiting the hospitals and see their healthcare providers face-to-face, hospitals are facing a low turnout. Hoping that this situation will not last long, these particular conditions have also shown to the owners of the private hospitals and to the managers of the public ones, how to transform difficulties in opportunities of growth and evolution, for example with the progressive integration of new ways of communication with patients, and in general of new ways of access to care. Also the development of telemedicine will definitely revolutionise the way of providing cares and assist patients, and the Italian government is working properly in order to favor this technologic transition and support as well the National Health Service, and all the hospitals that are daily working for its maintainance and its continuous improvement.
In the next months we will assist to a big funding of the Italian Health System, and this process will definitely include the private hospitals sector, which already daily operates, from the north to the south, to ensure the access to care to all the citizens.
A significant post-Covid growth of activity
Following the state of emergency declared in Portugal on March 12, there was an abrupt drop in activity in all Portuguese hospitals from the second half of March onwards, which worsened in April. In the case of private hospitals, activity fell by 67% in April, compared to the same month of the previous year.
It should be noted that the situation was transversal in the healthcare sector (be it public, private, or social entities) because the main causes were common to all:
  • guidelines from the Health Authorities to postpone specialty consultations and non-urgent surgeries and end activities such as dentistry
  • social distancing and confinement measures which led citizens to avoid leaving home, even to carry out their necessary health treatments.
Portuguese Private hospitals participated in the national fight against the pandemic from the beginning, in line with the rules of the national authorities. After the end of the state of emergency (May 4), citizens returned to private hospitals. There has been a very significant recovery in terms of specialty consultations. However, there is still a 50% drop in urgent episodes. In the case of surgeries, there has been an added effort to carry out not only normal activity but also to recover activity that could not be carried out in the previous months. With the correct management of the teams and optimization of the ORs, even on weekends, there has been a strong recovery in surgical activity, at the level that existed in 2019.
There is currently a strong apprehension about the impact of a second wave on health systems, there are also more and more voices (doctors, patients, etc.) disputing that health cannot stop again because there are many other diseases that need care. Private hospitals will continue to ensure safety for patients and health professionals.
Faced with the risk of an epidemic resumption: private hospitals and clinics are mobilizing
The French Federation of Private Hospitals held a press conference on Thursday 10 September to take stock of the health situation and the challenges of the new school year for private health establishments.
Faced with the observation of a resumption of the epidemic, Lamine Gharbi, president of the FHP, recalled that private hospitalisation was ready and fully mobilised. In all the territories, private health establishments are woking with their Regional Health Agencies in order to participate fully in the health response in each territory. "I am confident in the ability of health actors to cope because cooperation between public and private is now a major asset and we have the experience of the first wave," said Lamine Gharbi.
The FHP recalled that a new national deprogramming directive would not be desirable: it would be unjustified from a health point of view and would have serious medical consequences. The FHP asked that the next health measures be taken at the territorial level and built in consultation with all health actors in the territory.
The president of the FHP also warned about delays in care and called on the French to continue to seek treatment: "Unfortunately, it is not only Covid. The French must continue to seek treatment, knowing that the conditions of their care in health establishments are totally secure. »
Public-private collaboration needs a clear and transparent framework
By Carlos Rus, President of ASPE (Spanish Private Healthcare Alliance)
The Spanish private health sector reiterates its full availability to contribute to the care of those affected by COVID-19, as it has done since the beginning of the spread of the pandemic.
The national government has called on the private health sector to come to an agreement with each regional territory on the form of compensation for the resources made available to treat COVID patients, however, for the moment, the vast majority have not yet defined a remuneration framework with the hospitals involved.
Regarding activity, all healthcare areas have been significantly affected due to the management of the pandemic. A situation that has undoubtedly led the sector to a complicated situation filled with uncertainty.
Therefore, from the employer standpoint we are now requesting a framework that clearly and transparently regulates public-private collaboration as a joint measure to be adopted in the face of this second wave of coronavirus.
In the future, and in the face of new outbreaks, we must draw conclusions in different areas of the private sector that facilitate a better response from the National Health System:
  • Review and clearly specify the role of non-essential health centers, establishing, in even circumstances, reorganization measures among those whose operation is not vital for the care of these patients, taking into account the affectation of each area and especially outpatient centers.
  • The adoption of a regime of absolute compatibility for the free exercise of healthcare services between the private, private under contract and public spheres of these professionals while the pandemic lasts.
  • And at the fiscal level, the need to steadily establish a super-reduced VAT on purchases of health equipment and supplies.
Ultimately, the strengthening of public-private health collaboration would allow the best use of existing resources, while avaoiding the duplication of unnecessary investments.
The Asklepios Campus Hamburg is seeing a marked increase in the number of medical students applications
The number of students enrolled at foreign but also at state-run German universities who have applied for a continuation at the Asklepios Campus Hamburg (ACH) after their pre-clinical medical studies has risen significantly this year.
48% more students applied for the 5th semester (228 students versus 154 in 2019/20) and 24 students applied for the 7th semester (7 in 2019/20).
Most applications traditionally come from the three Hungarian universities of Budapest, Szeged and Pécs. This year the ACH received 187 applications, versus 122 in 2019/20, an increase of 65%.
Five new names have been added to the list of the non-Hungarian university cities from which applications have been received this year. Twice as many applications have been received from Poland this year due to the fact that in August last year, for the first time, difficulties arose in the recognition of medical studies completed in Poland by various German state examination offices. Seven students have applied from German state universities (2019/20: 3).
"I was particularly pleased with the high level of the applicants," says Stefanie Schwarz, Head of the Student Affairs and Dean's Office, summing up her impressions from this year's application phase. She is naturally pleased about the positive development in both the quantity and quality of the applications.
History of the Asklepios Campus Hamburg
Since 2008, medical students have had the opportunity to complete their clinical semesters in German on the modern Asklepios Campus Hamburg, in cooperation with the renowned Semmelweis University of Budapest, being the first branch of a foreign medical faculty in Germany and the first transnational cooperation between a European major state university and a leading private clinic operator in the field of medical education.
28 September
UEHP/WelcomeEurope webinar
EU funding programmes
30 September
online event UEHP/EAASM
The implementation of the Falsified Medicines
2 October
UEHP Council Meeting
26 October
EU Health Summit